A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.

Publication Type:

Journal Article

Source:

Cancer chemotherapy and pharmacology (2015)

Abstract:

To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer.